Hepatitis B Vaccine

(hep-uh-TIGHT-iss)

Trade Name(s):
Engerix-B
  • Injection (adult formulation)
  • 20 mcg/mL hepatitis B surface antigen
  • Injection (pediatric formulation)
  • 10 mcg/0.5 mL hepatitis B surface antigen

    Recombivax HB
  • Injection (adult formulation)
  • 10 mcg/mL hepatitis B surface antigen
  • Injection (pediatric/adolescent formulation)
  • 5 mcg/0.5 mL hepatitis B surface antigen
  • Injection (dialysis formulation
  • 40 mcg/mL hepatitis B surface antigen

    Indicates Canadian trade names.

    Class:  Vaccine, inactivated virus

      Action:
    Induces specific antibodies against hepatitis B virus.

      Indications:
    Induction of active immunity against hepatitis B virus among people of all ages who are currently or who will be at increased risk of infection with this virus. Routine vaccination is recommended for infants and adolescents. All individuals not receiving the hepatitis B vaccine are recommended to be vaccinated at 11 to 12 yr. In addition, vaccination is recommended in older unvaccinated adolescents at high risk. Vaccination is also indicated for those at high risk of exposure to or development of hepatitis B virus, such as health care personnel (ie, dentists; dental hygienists; nurses; oral surgeons; health care providers; surgeons; podiatrists; paramedical and ambulence personnel; patients and staff in hemodialysis units and hematology/oncology units; hemodialysis patients and patients with early renal failure before they require hemodialysis; blood bank and plasma fractionation workers; laboratory personnel handling blood, its products, and patients' specimens; dental, medical, and nursing students); hospital cleaning staff who handle potentially infectious waste; patients requiring frequent or large-volume blood transfusions or clotting factor concentrates; residents and staff of institutions for mentally handicapped; household and other intimate contacts of people with persistent hepatitis B antigenemia; infants born to HBsAg-positive mothers; populations with high incidence of hepatitis B virus (eg, Alaskan Eskimos, Indochinese refugees, Haitian refugees); people at increased risk because of their sexual practices (prostitutes, people who repeatedly contract STDs, homosexually active men, people with multiple sexual partners; international travelers; morticians; embalmers; prisoners; users of illicit injectable drugs; police and fire department personnel who render first aid or medical assistance. Risk factors for hepatitis C are similar to those for hepatitis B. Consquently, immunization with hepatitis B vaccine is recommended for individuals with chronic hepatitis C.

    Revaccination (booster doses):

    Adults and children with normal immune status: Antibody response lasts 10 yr.

    Hemodialysis patients: Vaccine protection is less complete and may persist only as long as antibody levels remain > 10 mIU/mL.

    Vaccinated people who experience percutaneous or needle exposure to HBsAg-positive blood: Serological tests to assess immune status is recommended. If inadequate levels exist, treat with a booster dose of vaccine.

    Nonresponders: Most people who do not initially respond to the primary series may develop adequate antibody concentrations after revaccination with a fourth or fifth dose or a new complete vaccine series.

      Contraindications:
    Hypersensitivity to yeast or any other component of vaccine.

      Route/Dosage:

    Preexposure and Postexposure Hepatitis B Prophylaxis

    Adults > 20 yr: Recombivax HB:
    IM 10 mcg at 0, 1, and 6 mo;
    Engerix-B:
    IM 20 mcg at 0, 1, and 6 mo.

    Adolescents 11 to 19 yr: Recombivax HB:
    IM 5 mcg at 0, 1, and 6 mo;
    Engerix-B:
    IM 10 mcg at 0, 1, and 6 mo.

    Infants and Children < 11 yr: Recombivax HB:
    IM 2.5 mcg at 0, 1, and 6 mo;
    Engerix-B:
    IM 10 mcg at 0, 1, and 6 mo.

    Infants of HBsAg-Positive or Negative Mothers: Recombivax HB:
    IM 5 mcg at 0, 1, and 6 mo;
    Engerix-B:
    IM 10 mcg at 0, 1, and 6 mo.

    Dialysis and Immunocompromised Patients: Recombivax HB:
    IM 40 mcg at 0, 1, and 6 mo;
    Engerix-B:
    IM 40 mcg at 0, 1, and 6 mo. Booster dose may be considered for patients undergoing dialysis if anti-Hbs level is < 10 mIU/mL 1 to 2 mo after third dose.

      Interactions:

    Immunosuppressants (including high-dose corticosteroids or radiation therapy): May result in an inadequate response to immunization.

    Yellow fever vaccine: May reduce antibody titer otherwise expected from yellow fever vaccine. Separate these vaccines by 1 mo.

    Anticoagulants: Use caution when administering to patients receiving anticoagulant therapy because coadministration may increase the immunization drug.

      Lab Test Interferences:
    None well documented.

      Adverse Reactions:

    CNS:
    Fatigue; weakness; headache; malaise; dizziness.
    DERM:
    Flushing; angioedema.
    EENT:
    Earache; pharyngitis.
    GI:
    Nausea; diarrhea.
    RESP:
    Upper respiratory infection.
    OTHER:
    Fever; pain; tenderness; pruritus; induration; erythema; ecchymosis; swelling; warmth or nodule formation at injection site; thrombocytopenia.

      Precautions:

    Pregnancy: Category C. Problems have not been reported and are unlikely. Use if woman is likely to be exposed to hepatitis B virus during or after pregnancy.

    Lactation: Undetermined.

    Elderly: Hepatitis B immunogenicity may be reduced in patients > 40 yr.

    Hypersensitivity: Anaphylaxis and symptoms of immediate hypersensitivity have occurred within hours of administering vaccine.

    Immunosuppressed patients: May require larger doses and may not respond to vaccine.

    Infection: Delay use of hepatitis B vaccine in presence of serious active infection except when withholding vaccine entails greater risk.

    Multiple sclerosis (MS): Although no casual relationship has been established, rare instances of MS exacerbation have been reported following administration of hepatitis vaccines and other vaccines.

    Severely compromised cardiopulmonary status: Administer vaccine with caution.

    Unrecognized hepatitis B infection: May be present at time of vaccination and vaccine may not prevent hepatitis B because of long incubation period.


    Patient Care Considerations

      Administration/Storage:

      Assessment/Interventions:

      Patient/Family Education:


    AtoZ Drug Facts · Copyright©2000 by Facts and Comparisons